SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001389933-18-000006
Filing Date
2018-02-14
Accepted
2018-02-13 21:17:28
Documents
1
Group Members
NATHAN FISCHEL, FARIBA GHODSIAN

Document Format Files

Seq Description Document Type Size
1 dafna13gsnss2017.txt SC 13G/A 10172
  Complete submission text file 0001389933-18-000006.txt   11849
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Subject) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-81034 | Film No.: 18606654
SIC: 2834 Pharmaceutical Preparations

Mailing Address 10990 WILSHIRE BOULEVARD SUITE 1400 LOS ANGELES CA 90024
Business Address 10990 WILSHIRE BOULEVARD SUITE 1400 LOS ANGELES CA 90024 (310) 954-3200
DAFNA Capital Management LLC (Filed by) CIK: 0001389933 (see all company filings)

IRS No.: 364334068
Type: SC 13G/A